Prelude Capital Management’s Trinity Biotech TRIB Stock Holding History

Prelude Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-106	Closed	-$95K	–	1857
2017 Q1	$95K	Buy	+106	New	+$99.4K	0.01%	800
2016 Q4	–	Sell	-229	Closed	-$454K	–	1778
2016 Q3	$454K	Buy	229 +114	+99%	+$213K	0.05%	331
2016 Q2	$196K	Sell	115 -3	-3%	-$5.07K	0.03%	504
2016 Q1	$207K	Hold	118	–	–	0.03%	541
2015 Q4	$209K	Buy	118 +33	+39%	+$58.4K	0.03%	545
2015 Q3	$146K	Sell	85 -106	-55%	-$256K	0.02%	720
2015 Q2	$518K	Hold	191	–	–	0.07%	301
2015 Q1	$552K	Sell	191 -55	-22%	-$152K	0.08%	307
2014 Q4	$646K	Sell	246 -414	-63%	-$1.07M	0.09%	240
2014 Q3	$1.81M	Buy	660 +93	+16%	+$302K	0.25%	76
2014 Q2	$1.96M	Buy	567 +137	+32%	+$487K	0.26%	72
2014 Q1	$1.56M	Buy	430 +190	+79%	+$747K	0.21%	103
2013 Q4	$905K	Buy	+240	New	+$864K	0.15%	167
2013 Q3	–	Sell	-206	Closed	-$521K	–	1836
2013 Q2	$521K	Buy	+206	New	+$513K	0.11%	242

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Prelude Capital Management's TRIB Position: Q2 2017 in Review

Prelude Capital Management sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 106 shares — an estimated $95K sold.

Prelude Capital Management first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $1.96M in Q2 2014. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

Prelude Capital Management reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
Prelude Capital Management sold 106 Trinity Biotech shares in Q2 2017, an estimated $95K.
Prelude Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
Prelude Capital Management's Trinity Biotech position peaked at $1.96M in Q2 2014.
56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.